blood transfusion on postoperative complications following laparoscopic hysterectomy done for benign indications. MATERIALS AND METHODS: This is a retrospective national database cohort study from the academic centers affiliated with the American College of Surgeons National Surgery Quality Improvement Program (ACS-NSQIP). Data from individuals who underwent laparoscopic hysterectomy for benign indications between 2012 and 2016 were collected for analysis. Patients were identified based on their CPT and ICD codes. Univariate analysis using ANOVA and chisquared tests were performed to evaluate associations between transfusion requirement and patient demographics and comorbidities. Binary logistic regression analysis was completed to determine independent associations of transfusion requirement with postoperative complications. RESULTS: A total of 96,579 patients who underwent laparoscopic hysterectomy for benign indications between 2012 and 2016 were collected for analysis. In total, 1,381 (1.4%) patients received a perioperative transfusion, while 95,198 (98.5%) did not. Patients receiving a perioperative transfusion were more likely to be nonwhite (p<0.001), and younger (p<0.001). They were also more likely to have multiple comorbidities such as anemia (p<0.001), diabetes (p¼0.018), renal failure requiring dialysis (p<0.001), a bleeding disorder (p<0.001). Using multivariate regression analyses, perioperative transfusion was found to be independently associated with multiple infectious comorbidities including organ space infection (OR ¼ 1.9; 95% CI ¼ 1.0, 3.7; p ¼ 0.032), total wound comorbidity (OR ¼ 2.0; 95% CI ¼ 1. 
OBJECTIVES:
To determine the oral morphine equivalents (OMEs) prescribed and refill rates following hysterectomy and hysteroscopy in the setting of statewide legal changes to opioid prescribing across two states. MATERIALS AND METHODS: Patients undergoing hysterectomy (including concomitant procedures for oncology and urogynecology cases) and hysteroscopy (diagnostic and operative) from January 2011 through July 2018 were identified using Current Procedural Terminology (CPT) procedure codes in our institution's databases in two affiliated hospitals (Arizona and Florida). Hysterectomy was chosen as the most invasive gynecologic procedure requiring the most postoperative narcotic medication, while hysteroscopy was chosen as the least invasive necessitating the fewest postoperative narcotics. Opioid prescriptions at time of discharge and refills within 30 days were identified and converted to OMEs. OMEs were calculated per quarter year. In Arizona, the Arizona Opioid Epidemic Act was passed in January 2018 and went into effect in April 2018; this limited prescriptions to 90 OMEs per day for five days. In Florida, House Bill 21 restricted prescribing of Schedule II medications to three days for acute pain or up to seven days when medically necessary. The law was signed in March 2018 and took effect in July 2018. Prior to these changes, there were a number of informal provider-led initiatives in both departments to reduce opioid prescribing given the media attention to the subject. Our study compares prescribed OMEs and refill rates before and after the first quarter in 2018. RESULTS: In Arizona, 2204 hysterectomies were performed during the study period; 1077 (49%) were vaginal, 1002 (45%) were laparoscopic/robotic, and 125 (6%) were abdominal. There were 1196 hysteroscopies. Median OMEs for all four procedure types were unchanged before and after 2018 (225). The overall opioid refill rate decreased, from 10% prior to 2018 versus 4% after 2018 (p value 0.0004). In Florida, there were 1459 hysterectomies; 380 (26%) vaginal, 936 (64%) laparoscopic/robotic, and 143 (10%) abdominal. There were 972 hysteroscopies. Overall median OMEs decreased from 245 prior to 2018 to 0 after 2018, p value <0.0001. The opioid refill rate decreased, from 8% prior to 2018 versus 4% after 2018 (p value 0.01). Figure 1 shows the OME trends by surgical procedure and hospital site over time. CONCLUSION: Many state governments have implemented laws to encourage safe prescribing of controlled substances. Our study demonstrates that the legislative changes sustained preexisting decreases in opioid prescribing in Florida but not in Arizona. In addition, significant reductions in opioid refills after 2018 were observed in both sites. Gynecologic surgeons must not only participate in safe prescribing practices, but also educate patients about pain control alternatives to further decrease opioid dependence and misuse. OBJECTIVES: To compare rates of unscheduled clinician-patient encounters in patients who have undergone benign minimally invasive hysterectomy before and after the institution of the Enhanced Recovery After Surgery (ERAS) program. MATERIALS AND METHODS: A retrospective analysis evaluating women who underwent minimally invasive hysterectomy for benign indications was completed. We compared patients who underwent surgery the year prior to the implementation of an ERAS protocol (2012) with those who underwent surgery one year after ERAS was implemented (2014). The primary outcome was unscheduled clinician-patient encounters, which included patient-initiated phone calls, emergency room visits, and unscheduled post-operative office visits. Additional covariates measured include number of procedures performed in addition to the hysterectomy, operative time, readmission, estimated blood loss, and concomitant sling. RESULTS: A total of 90 women were included in the pre-ERAS group and 110 in the post-ERAS group. The two groups had no significant demographic differences. After implementation of ERAS, there was a significant increase in unscheduled patient encounters. The number of patients who initiated post-operative phone calls within two weeks of their surgery date increased from 39% (n¼35) before ERAS implementation to 68% (n¼75) after ERAS implementation (p¼<0.0001). Furthermore, additional medical care including any phone calls, inperson unscheduled post-operative visits or emergency room visits also significantly increased after ERAS implementation from 42% (n¼38) to 75% (n¼82) (p¼0.0001, OR 4.01). The odds of a patient seeking in-person medical care within two weeks post-operatively were three times higher if a concomitant sling procedure was performed regardless of ERAS protocol (p¼0.04, OR 3.16). There were no significant differences in readmission rates, operative time, blood loss, or emergency room visits between the two groups. CONCLUSION: ERAS protocol has been shown to be beneficial and safe in gynecologic surgery; however, when applied to benign hysterectomy, the gynecologist may need to anticipate an increase in the volume of unscheduled patient encounters. Managing this burden may require allocation of additional resources such as increased staff assistance or designated clinical time by the physician. Further research on ways to minimize unscheduled patient encounters after ERAS implementation should be evaluated.
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Rachael Haverland: Nothing to disclose; Meenal Misal: Nothing to disclose; Megan Wasson: Nothing to disclose; Johnny Yi: Nothing to disclose. OBJECTIVES: To describe postoperative pain and functional activity after transvaginal native tissue reconstructive surgery with apical suspension and retropubic synthetic midurethral sling (MUS) and to compare these outcomes between patients receiving uterosacral ligament suspension (USL) and sacrospinous ligament fixation (SSLF).
MATERIALS AND METHODS:
This planned secondary analysis of a 2x2 factorial randomized trial included 374 women randomized to receive ULS (n¼188) or SSLF (n¼186) to treat both Stages 2-4 apical vaginal prolapse and stress incontinence between 2008 and 2013 at 9 medical centers. Participants also randomized to receive perioperative pelvic muscle therapy or usual care. All patients received transvaginal native tissue repairs and a MUS. Participants completed the Surgical Pain Scales (0-10 numeric rating scales; higher scores ¼ greater pain) and Activity Assessment Scale (AAS) (0-100; higher score ¼ higher activity) prior to surgery and at 2 weeks, 4-6 weeks, and 3 months postoperatively. The SF-36 was completed at baseline, 6, 12, and 24 months after surgery; the Bodily Pain, Physical Functioning, and Role-Physical subscales were used for this analysis (higher scores ¼ less disability). Self-reported pain medication use was also collected. RESULTS: Before surgery, average pain at rest and during normal activity were (adjusted mean AE standard error) 2.2+0.2 and 2.8+0.3 (range 0-10 and 0-9, respectively); both increased slightly from baseline at 2 weeks (+0.7 for both, p<0.01 compared to pre-surgery) then decreased below baseline at 3 months (-0.9 and -1.1 respectively, p<.001), with no differences between surgical groups. Pain during exercise/strenuous activity and worst pain decreased below baseline levels at 4-6 weeks (-1.3, p¼.01 and -1.0, p¼.002) and 3 months (-2.0 and -1.5, p<.0001) without differences between surgical groups. Functional activity as measured by the AAS improved from baseline at 4-6 weeks (+9.2, p<.0001) and 3 months (+13.8, p<.0001). SF-36 Bodily Pain, Physical Functioning and Role-Physical Scales demonstrated significant improvements from baseline at 6, 12, and 24 months with no differences between groups (24 months: +5.6, +5.8 and +4.7 respectively, p<.0001 for each). Use of narcotic pain medications was reported by 14% of participants prior to surgery, 54% at 2 and 26% at 4-6 weeks post-operatively; thereafter, use was similar to baseline rates until 24 months when it decreased to 7%. Use of non-narcotic pain medication was reported by 48% of participants prior to surgery, 69% at 2 weeks and similar to baseline at 3 months; thereafter use dropped steadily to 27% at 2 years. CONCLUSION: Pain and functional activity improve for up to 2 years after native tissue reconstructive surgery with ULS or SSLF and MUS for stage 2-4 pelvic organ prolapse. On average, immediate postoperative pain is low and improves to below baseline levels by 4-6 weeks.
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